ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$1.94 USD
+0.02 (1.04%)
Updated May 17, 2024 04:00 PM ET
After-Market: $1.93 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PRQR 1.94 +0.02(1.04%)
Will PRQR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRQR
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Is ProQR (PRQR) Stock a Solid Choice Right Now?
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates
Other News for PRQR
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Buy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footing
ProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potential
ProQR Announces First Quarter 2024 Operating and Financial Results
ProQR Therapeutics Reports Quarterly Financials